Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis.
Launched by CHANGHAI HOSPITAL · Mar 7, 2022
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Chronic pancreatitis(CP)is a chronic progressive fibro-inflammatory disease of the pancreas induced by a wide range of factors including genetic and environmental elements, with recurrent abdominal pain and pancreatic secretion insufficiency as its major clinical signs. Chronic pancreatitis is not only a tough disease of the gastrointestinal system but also a worldwide medical problem. At present, the MESS (medicine-extracorporeal shock wave lithotripsy-endoscopic retrograde cholangiopancreatography-surgery)formed by changhai hospital in CP diagnosis and treatment is gradually becoming matu...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. symptomatic adult patients diagnosed with chronic pancreatitis and main pancreatic duct positive stones(\>5mm in diameter)
- • 2. no ERCP and ESWL history before the admission
- • 3. provides informed consent
- Exclusion Criteria:
- • 1. suspected to have malignant tumors;
- • 2. history of pancreatic surgery or gastrojejunostomy (Billroth II);
- • 3. with end-stage disease;
- • 4. with contraindications to ESWL or ERCP, such as pregnancy, abdominal aortic aneurysm, etc.
- • 5. acute pancreatitis within 3 days
- • 6. pancreatic ascites
About Changhai Hospital
Changhai Hospital is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a commitment to excellence, the hospital integrates cutting-edge medical technologies and a multidisciplinary approach to patient care. Changhai Hospital actively collaborates with research organizations and healthcare professionals to conduct rigorous clinical trials aimed at developing new treatments and improving patient outcomes. By prioritizing patient safety and ethical standards, the hospital plays a pivotal role in contributing to the advancement of medical knowledge and the enhancement of therapeutic options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Trial Officials
Zhuan Liao, MD
Principal Investigator
Changhai Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials